quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 13, 2026

Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results

View original at globenewswire.com
Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results WEST PALM BEACH, Fla., July 13, 2026 (GLOBE NEWSWIRE) -- Solitron Devices, Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is no assurance that the strategic alternatives review will result in a merger, sale, acquisition, tender offer, or special dividend, and the Company will not make further announcements until the Board approves a specific course of action.

    60% confidence
  • Revenue is expected to continue at the fiscal Q1 2027 level or greater for the remainder of fiscal year 2027, driven by strong backlog.

    60% confidence
  • The next AMRAAM order is currently expected in the fiscal third quarter.

    60% confidence
  • Net income in the fiscal 2027 first quarter was impacted by a $0.33 million increase to the contingent consideration related to the MEI earn-out payment, based on a large order received after the end of the fiscal quarter.

    60% confidence
  • No actual income taxes were due despite the income statement reflecting income tax expense, because the Company has deferred tax assets from previous net operating losses.

    60% confidence
  • Defense procurement processes tend to move slowly.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results — Source | Via News | pt.VIA.NEWS